Once again, GlaxoSmithKline has the U.S. Justice Department on its tail. Prosecutors are investigating bribery allegations that Glaxo faces in China, trying to determine whether the drugmaker violated U.S. law.
In an InformationWeek profile, GlaxoSmithKline touts the benefits of a new online collaboration system, including the savings on travel expenses and satisfaction of the pharma giant's customers.
Coming into 2013 GlaxoSmithKline highlighted a cancer vaccine as one of its brightest late-phase candidates. Yet, like many cancer vaccines before it, MAGE-A3 has disappointed at the final hurdle.
GlaxoSmithKline and partner Theravance are closing in on an important advisory committee meeting for their experimental lung drug Anoro Ellipta next week. And FDA staff has noted in a briefing document that the combination therapy for COPD was effective at two doses, Bloomberg reported.
GlaxoSmithKline is in the middle of a firestorm in China, accused of bribery and potentially facing massive fines from the government. The very public scandal has left a chill on business for it and other drugmakers in this key market. But even with all of that, would the British drugmaker actually pull out of the most populous country in the world, on which it has bet heavily?
GlaxoSmithKline may be on the verge of bidding goodbye to two of its drinks brands. Japan's Suntory Beverage & Food is in advanced talks to buy Lucozade and Ribena, the brands GSK put up for sale early this year, for more than £1 billion ($1.6 billion), Reuters reports.
GlaxoSmithKline experienced a major R&D setback today, reporting that its targeted cancer immunotherapy MAGE-A3 failed its first co-primary endpoint in a Phase III study for melanoma, failing to beat out a placebo in spurring disease-free survival.
It's never good when authorities talk openly of imposing "astronomical" fines on a drugmaker. But China officials have suggested that about GlaxoSmithKline, even as a spray of Chinese news reports accuse former GSK China leader Mark Reilly of fostering a culture that encouraged doing whatever neccessary to hit huge sales goals.
Contrary to GlaxoSmithKline 's official explanations, Chinese police say rogue executives didn't engineer $489 million in alleged bribes. The company itself organized the scheme, they say, and made sure internal auditors didn't uncover it.
The recent, and very public, Chinese investigation into bribery allegations against GlaxoSmithKline and others has doctors running scared, making it tough for everyone to sell drugs there.